Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle, WA, United States of America; Advancing Integrated Mental Health Solutions (AIMS) Center, University of Washington, Seattle, WA, United States of America; Center of Innovation for Veteran-Centered and Value-Driven Care, Health Services Research & Development, VA Puget Sound, Seattle, WA, United States of America.
Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle, WA, United States of America; Advancing Integrated Mental Health Solutions (AIMS) Center, University of Washington, Seattle, WA, United States of America.
Contemp Clin Trials. 2024 Nov;146:107700. doi: 10.1016/j.cct.2024.107700. Epub 2024 Sep 23.
The gold-standard treatment for opioid use disorder (OUD) is medication for OUD (MOUD). However, less than a quarter of people with OUD initiate MOUD. Expanding the Collaborative Care Model (CoCM) to include primary care patients with OUD could improve access to and initiation of MOUD. This paper presents the methods and baseline sample characteristics of a Hybrid Type 2a trial comparing the effectiveness of CoCM for OUD and co-occurring mental health symptoms (MHS) to CoCM for MHS only.
42 primary care clinics were cluster randomized and 254 primary care patients with OUD and elevated MHS were enrolled. Recruitment was terminated early by the Data and Safety Monitoring Board for futility. Participants completed research assessments at baseline, 3 months, and 6 months. The multiple primary outcomes were past-month number of days of nonmedical opioid use and SF12 Mental Health Component Summary (MCS) scores.
MCS scores were over a standard deviation below the national mean (M = 34.5). Nearly half (47.6 %) of participants had previously overdosed in their lifetimes. Three quarters (76.0 %) were already being prescribed MOUD at baseline, only 30.4 % reported non-medical use of opioids, and only 33.9 % reported being bothered by opioid cravings.
The unexpectedly high proportion of enrollees already prescribed MOUD at baseline indicates that most patients were in the maintenance rather than acute phase of treatment. Challenges identifying and enrolling patients in the acute phase of OUD treatment implies that intervention effectiveness will depend on its success preventing the discontinuation of MOUD rather than initiating MOUD.
阿片类药物使用障碍(OUD)的金标准治疗方法是阿片类药物使用障碍药物治疗(MOUD)。然而,只有不到四分之一的 OUD 患者开始接受 MOUD。将协作式护理模式(CoCM)扩展到包括患有 OUD 的初级保健患者,可以增加获得和开始 MOUD 的机会。本文介绍了一项比较 CoCM 治疗 OUD 和共病精神健康症状(MHS)与 CoCM 仅治疗 MHS 的有效性的 2a 型混合试验的方法和基线样本特征。
42 家初级保健诊所被整群随机分组,254 名患有 OUD 和升高的 MHS 的初级保健患者入组。数据和安全监测委员会因无效而提前终止了招募。参与者在基线、3 个月和 6 个月时完成研究评估。主要结局是过去一个月非医疗性阿片类药物使用天数和 SF12 心理健康成分综合得分(MCS)。
MCS 得分低于全国平均水平一个标准差(M=34.5)。近一半(47.6%)的参与者一生中曾有过过量用药的经历。四分之三(76.0%)的参与者在基线时已经被开处 MOUD,只有 30.4%报告非医疗性使用阿片类药物,只有 33.9%报告被阿片类药物成瘾困扰。
出乎意料的是,基线时已被处方 MOUD 的参与者比例很高,这表明大多数患者处于治疗的维持期而非急性期。在识别和招募 OUD 治疗急性期患者方面存在挑战,这意味着干预效果将取决于其成功预防 MOUD 的停药,而不是启动 MOUD。